Few clinical trials incorporate studies of evolutionary cancer biology, despite the frequent emergence of acquired resistance to anticancer therapies. This problem motivated the first CRUK Marshall Symposium on Cancer Evolution in May 2017, which provided a forum for evolutionary and ecological theorists, cancer biologists, and clinicians to consider how evolutionary biology might inform improvements in cancer medicine. Herein, we discuss the key themes and opportunities for the future.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
12 September 2017
In the online version of this article, CRUK should have been included in all references to the Cancer Research UK (CRUK) Marshall Symposium. In the acknowledgements section, a minor word change from funding to supporting has been made. This information has now been corrected in the online pdf and html versions of the manuscript.
References
Sidow, A. & Spies, N. Concepts in solid tumor evolution. Trends Genet. 31, 208–214 (2015).
Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
Chamary, J. V., Parmley, J. L. & Hurst, L. D. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat. Rev. Genet. 7, 98–108 (2006).
Siravegna, G. et al. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 10.1038/nrclinonc.2017.14 (2017).
Newman, A. M, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015)
Sodir, N. M. & Evan, G. I. Finding cancer's weakest link. Oncotarget 2, 1307–1313 (2011).
Goldie, J.H . & Coldman, A.J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44, 3643–3653 (1984).
Enriquez-Navas, P. M . et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl Med. 8, 327ra324 (2016).
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
Acknowledgements
We would like to thank Cancer Research UK and Alison Howe for supporting the CRUK Marshall Symposium and Safia Danovi and Laurence Dudley for logistical support. The Cancer Research UK (CRUK) Marshall Symposia were conceived to bring together a small group of world-leading researchers across a range of disciplines to discuss and debate the biggest challenges in cancer research. The meeting series was named in memory of Professor Chris Marshall, a cell signalling pioneer, dedicated mentor and long-time CRUK-funded researcher, in recognition of his outstanding contribution to science.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1
Names and affiliations of participants in the Marshall Symposium 2017 (PDF 94 kb)
Rights and permissions
About this article
Cite this article
Sahai, E., Swanton, C. & and Marshall Symposium. Evolution and cancer medicine — transformative insights. Nat Rev Clin Oncol 14, 709–710 (2017). https://doi.org/10.1038/nrclinonc.2017.121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.121
